Every 424B that Mobix Labs, Inc. (MOBX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MOBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MOBX filings page.
Mobix Labs, Inc. (MOBX) filed a prospectus supplement covering an offering of up to 3,744,161 shares of Class A common stock, updating investors with a new 8‑K and its June 30, 2026 Form 10‑Q. Mobix also entered into a Merger Agreement to acquire Vision Aerial, Inc. for $3.0 million in cash plus Mobix Class A shares valued at $12.0 million, with the share count based on a 20‑day VWAP capped between $2.00 and $3.00 per share.
For the nine months ended June 30, 2026, Mobix generated net revenue of $3.6 million, down from $8.0 million a year earlier, and recorded a net loss of $32.8 million. Operating cash outflow was $14.7 million, and cash on hand was $2.1 million against total liabilities of $26.7 million, prompting management to state there is substantial doubt about the company’s ability to continue as a going concern. To address liquidity, Mobix issued Series A 10% Convertible Preferred Stock, multiple senior secured convertible notes with floating conversion prices, and equity for debt settlements, all of which add meaningful potential dilution to common shareholders.
Mobix Labs, Inc. (MOBX) filed a prospectus supplement covering up to 2,412,711 shares of Class A common stock, updating its S-1 prospectus with a new 8-K and 10-Q. The shares trade on Nasdaq under “MOBX”; the August 17, 2026 closing price was $1.26.
The company agreed to acquire Vision Aerial, Inc. for $3.0 million in cash plus $12 million in MOBX stock, with the stock portion issued at a 20‑day volume‑weighted average price, floored at $2.00 and capped at $3.00 per share, subject to customary adjustments and approvals. For the nine months ended June 30, 2026, Mobix Labs generated $3.6 million in revenue and recorded a net loss of $32.8 million, with cash used in operations of $14.7 million.
As of June 30, 2026, the company had $2.1 million in cash, total assets of $34.9 million, liabilities of $26.7 million, and an accumulated deficit of $183.4 million. Management states there is substantial doubt about Mobix Labs’ ability to continue as a going concern without additional financing, and recent financing includes convertible notes and Series A 10% Convertible Preferred Stock with variable‑price conversion features that may be dilutive to common shareholders.
Mobix Labs, Inc. is registering the resale by existing holders of up to 3,744,161 shares of Class A Common Stock, including 2,000,000 shares tied to Series A 10% Convertible Preferred Stock and a Preferred Stock Purchase Warrant, 1,207,942 shares issued to lenders in debt settlements, 71,267 litigation settlement shares, and 464,952 RaGE Systems earnout shares. The company is not selling shares itself and will receive no proceeds from these resales, though it may receive up to $6,000,000 if the Preferred Warrant is exercised, for working capital and general corporate purposes.
As of June 8, 2026, 14,998,187 Class A and 200,491 Class B shares were outstanding, and the Offered Securities would represent about 25% of Class A shares. The prospectus warns that resale of these shares, together with other registered resale securities, could significantly depress the trading price; the stock last closed at $1.97 on July 16, 2026. Mobix highlights substantial risks, including recurring operating losses, an accumulated deficit of $166.6 million, substantial doubt about its ability to continue as a going concern, expected future capital raises (which may be dilutive), reliance on a limited number of customers, material weaknesses in internal controls, and the possibility of Nasdaq delisting if listing standards are not maintained.
The company is an emerging growth company and smaller reporting company, using reduced disclosure and internal control requirements, and recently effected a 1-for-10 reverse stock split to regain Nasdaq bid-price compliance. Recent financing and strategic actions include preferred stock and warrant financing with Kips Bay Select, LP, convertible notes with Leviston Resources, LLC (partly converted into equity and partly outstanding), share-for-debt settlements, earnout structures tied to acquisitions of EMI Solutions and RaGE Systems, and non-binding letters of intent for additional acquisitions, all of which may lead to further share issuance and dilution if completed.
Mobix Labs, Inc. files a Prospectus Supplement to its Form S-1 covering up to 2,412,711 shares of Class A common stock. The supplement incorporates Form 8-K updates describing (1) a potential acquisition discussion with Vision Aerial, (2) expected corrective amendment and a resale registration (including approximately 3,300,000 shares for Kips Bay and 1,239,613 shares for five other selling stockholders), (3) settlements that satisfied approximately $3.74 million of liabilities, and (4) a new senior secured convertible note issued to Leviston Resources with a $2,800,000 principal amount (consideration funded $2,333,333.33), 10% interest and an October 22, 2026 maturity.
The company expects a July 2026 stockholder meeting to seek approvals for issuances tied to the Kips transaction, charter and equity-plan amendments, and additional shares for fundraising and acquisitions. The Vision Aerial acquisition and financing plans remain subject to due diligence, required approvals, and the availability of financing.
Mobix Labs, Inc. files a prospectus supplement to its Form S-1 registering up to 2,412,711 shares of Class A common stock. The supplement incorporates material disclosed in the Company’s Form 8-K and Form 10-Q.
Separately, the Company amended and expanded a senior secured convertible note with Leviston, increasing funded amount to $3,333 (aggregate principal reported as $4,000 inclusive of original issue discount); the original note was satisfied through conversion into 2,500,000 shares. Management reports cash of $2,563 and an accumulated deficit of $166,566 as of March 31, 2026 and states there is substantial doubt about the Company’s ability to continue as a going concern absent additional financing.
Mobix Labs, Inc. is registering the resale of up to 2,500,000 shares of Class A Common Stock, representing shares issuable upon conversion of a $3,000,000 senior secured convertible promissory note held by Leviston Resources, LLC. The company will receive no proceeds from these resales and the registration covers shares that would equal approximately 23.94% of outstanding Class A Common Stock as of April 16, 2026. The prospectus warns that the resale or market perception of these sales could materially depress the trading price of the Class A Common Stock.
Mobix Labs, Inc. files a prospectus supplement registering up to 2,412,711 shares of Class A common stock. The supplement updates the prospectus with information from Current Reports on Form 8-K filed April 3, 2026 and April 9, 2026. The company’s Class A shares trade on Nasdaq under the symbol MOBX; the closing price was $3.04 on April 8, 2026.
Mobix Labs, Inc. files a Prospectus Supplement amending its Form S-1 to register up to 24,127,116 shares of Class A Common Stock.
The supplement incorporates a Form 8-K disclosing results from the March 23, 2026 Annual Meeting: holders representing 43,982,421 Class A shares and 2,004,901 Class B shares (approximately 52.86% voting power as of February 27, 2026) were present or represented. Stockholders approved director elections, ratification of the independent auditor, a reverse stock split proposal, and a warrant proposal. The Company’s Class A shares trade on Nasdaq under MOBX, with a closing price of $0.4588 on March 24, 2026.
Mobix Labs, Inc. registers the resale of up to 24,127,116 shares of Class A Common Stock by selling stockholders. The resale prospectus covers Offered Securities held by third parties (including 1,268,252 Warrant Shares and 3,856,854 RaGE consideration shares) and states the company will not receive proceeds from resale by the Selling Stockholders.
The prospectus discloses 101,072,226 shares of Class A Common Stock outstanding as of January 31, 2026. It also states that, if certain warrants are exercised for cash, the company would receive aggregate gross proceeds of approximately $15.6 million. The filing warns that the Offered Securities would represent approximately 23.9% of outstanding Class A shares as of January 31, 2026 and that such sales could materially depress the market price.
Mobix Labs, Inc. is conducting a primary offering of up to 30,000,000 shares of Class A common stock at $0.20 per share, for gross proceeds of about $6.0 million. After placement fees and expenses, Mobix estimates net proceeds of approximately $5.135 million, which it plans to use for working capital and general corporate purposes.
The deal is a best-efforts offering through D. Boral Capital, with no minimum amount and no escrow; funds become immediately available to the company even if the maximum is not sold. Existing holders face immediate and substantial dilution, as the share count would rise from 64,308,034 to 94,308,034 Class A shares if the full amount is issued, and additional dilution could come from options, RSUs, warrants and earnout shares.
The company highlights going concern risks and the need for additional capital, and it is currently not in compliance with Nasdaq’s minimum bid price and market value listing standards, with an extension to regain compliance by April 27, 2026. Failure to comply could lead to delisting, which may reduce liquidity and make future financing more difficult.
Mobix Labs, Inc. filed Prospectus Supplement No. 5 covering up to 15,373,309 shares of Class A common stock. The supplement incorporates a recent update: the company amended certain outstanding warrants covering 13,375,490 shares so they are classified as equity rather than liabilities, and issued an additional warrant for 1,000,000 shares with a $1.08 exercise price. The company states no cash consideration was exchanged for these amendments.
Mobix also reported two debt-for-equity exchanges: 227,954 shares issued for $204,931.07 of obligations and 687,894 shares for $510,791.67 of indebtedness. Nasdaq granted an extension to regain the $1.00 minimum bid price through April 27, 2026. The company notes prior warrant liabilities of approximately $6.3 million are now reflected within stockholders’ equity. Mobix’s Class A common stock closed at $0.6929 on October 30, 2025.
Mobix Labs, Inc. launched an at-the-market program to sell up to $15.8 million of Class A Common Stock through Roth Capital Partners. Sales may occur from time to time under an ATM Sales Agreement, and Roth will be deemed an underwriter under the Securities Act.
The company will pay a 3.0% commission on gross proceeds and expects to use net proceeds for working capital. As of October 9, 2025, Class A shares outstanding were 58,624,989. The filing notes the company’s use of Form S-3 capacity and prior sales during the lookback period.
The risk disclosures highlight potential dilution from future issuances and note that entering into and selling under the ATM could prompt a dispute under a prior equity line agreement, which could lead to claims. Orders will be executed at company-imposed price limits with no escrow arrangement.